Overview
Synthetic cannabinoid dependence involves the compulsive use of synthetic cannabinoid receptor agonists (SCRA), leading to adverse health outcomes including psychiatric disturbances and neurological sequelae. These substances are often more potent than natural cannabis and can cause severe toxicity due to their varied chemical compositions. 123Diagnosis
Clinical Presentation: Symptoms may include confusion, visual hallucinations, ataxia, and psychiatric reactions such as anxiety and psychosis. 3
Laboratory Testing: Identification of specific SCRA compounds in biological samples via advanced analytical techniques like LC-MS/MS is crucial for diagnosis. 2
Demographic Considerations: Higher incidence in young males, particularly European and Māori populations, should guide clinical suspicion. 1Management
Detoxification: Supportive care including monitoring for withdrawal symptoms and managing acute complications. Specific pharmacological agents for withdrawal are not detailed in the provided abstracts.
Psychiatric Support: Address psychiatric symptoms with appropriate psychotherapeutic interventions and, if necessary, antipsychotic medications (e.g., atypical antipsychotics). 3
Behavioral Therapy: Cognitive-behavioral therapy (CBT) and motivational interviewing are recommended adjuncts to pharmacological management. 1Special Populations
Pediatrics: Limited data; heightened vigilance for neurological sequelae and psychiatric effects is advised. 3
Elderly: Increased risk of severe adverse reactions due to potential comorbidities and altered pharmacokinetics; close monitoring required. 1
Comorbidities: Patients with pre-existing psychiatric conditions may experience exacerbated symptoms; tailored psychiatric support is essential. 3Key Recommendations
Monitor and Identify Specific SCRA Compounds: Utilize advanced analytical methods like LC-MS/MS for accurate identification of synthetic cannabinoids in patients presenting with toxicity (Evidence: Moderate) 2
Prioritize Psychiatric and Neurological Assessment: Given the high incidence of psychiatric reactions and neurological symptoms, comprehensive psychiatric and neurological evaluations are crucial (Evidence: Moderate) 13
Tailor Treatment to Demographic Risk Factors: Consider demographic factors such as age, gender, and ethnicity when assessing risk and planning interventions (Evidence: Expert opinion) 1
Implement Supportive and Psychotherapeutic Interventions: Use supportive care and behavioral therapies like CBT to manage dependence and psychiatric symptoms (Evidence: Moderate) 13References
1 Robson H, Braund R, Glass M, Ashton J, Tatley M. Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre. Clinical toxicology (Philadelphia, Pa.) 2021. link
2 Hill SL, Dunn M, Cano C, Harnor SJ, Hardcastle IR, Grundlingh J et al.. Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification. Clinical chemistry 2018. link
3 Kak M, Mikhail F, Yano ST, Guan R, Lukas RV. Buzz Juice: Neurological sequelae of synthetic cannabinoids. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2017. link
4 Papadopoulos EA, Cummings KR, Marraffa JM, Aldous KM, Li L, Ahmad N. Reports of adverse health effects related to synthetic cannabinoid use in New York State. The American journal on addictions 2017. link
5 Piggee C. Investigating a not-so-natural high. Analytical chemistry 2009. link
6 McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL et al.. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. Journal of medicinal chemistry 2003. link